|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Emory University |
|---|---|
| Collaborator: |
National Institute of Neurological Disorders and Stroke (NINDS) |
| Information provided by: | Emory University |
| ClinicalTrials.gov Identifier: | NCT00021866 |
Purpose
The purpose of this study is to determine if antiepileptic drugs (AEDs) differ in their neurodevelopmental effects. Specifically, do the children of the women with epilepsy differ in their behavioral and cognitive development depending on which AED their mother takes during pregnancy?
| Condition | Intervention |
|---|---|
|
Epilepsy Seizure Cognition Disorders |
Behavioral: Differential Abilities Scale Behavioral: Neuropsychological Testing |
| Study Type: | Observational |
| Study Design: | Observational Model: Family-Based Time Perspective: Prospective |
| Official Title: | Neurodevelopmental Effects of Antiepileptic Drugs II: the NEAD Study |
Venous blood for AED levels Cord Blood for G6PD, Homocysteine Saliva for drug metabolizing enzymes, antioxidant enzymes, DNA repair enzymes, drug membrane transporter proteins and folate-related genes
| Enrollment: | 331 |
| Study Start Date: | September 2000 |
| Estimated Study Completion Date: | August 2011 |
| Primary Completion Date: | August 2010 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Carbamazepine
Children and their mothers exposed to Carbamazepine monotherapy in utero
|
Behavioral: Differential Abilities Scale
IQ measurement at 3, 4.5 and 6 years of age
Other Name: DAS
Behavioral: Neuropsychological Testing
Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Other Names:
|
|
Phenytoin
Children and their mothers exposed to phenytoin in utero
|
Behavioral: Differential Abilities Scale
IQ measurement at 3, 4.5 and 6 years of age
Other Name: DAS
Behavioral: Neuropsychological Testing
Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Other Names:
|
|
Lamotrigine
Children and their mothers exposed to Lamotrigine in utero
|
Behavioral: Differential Abilities Scale
IQ measurement at 3, 4.5 and 6 years of age
Other Name: DAS
Behavioral: Neuropsychological Testing
Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Other Names:
|
|
Valproate
Children and their mothers exposed to Valproate in utero
|
Behavioral: Differential Abilities Scale
IQ measurement at 3, 4.5 and 6 years of age
Other Name: DAS
Behavioral: Neuropsychological Testing
Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
Other Names:
|
This is a prospective investigation enrolling 285 to 380 women with epilepsy during the first two trimesters of their pregnancies. There are 25 clinical centers as well as the database center. The women will be taking one of the following AEDs: carbamazepine, phenytoin, valproate, or lamotrigine. Cognitive and behavioral testing of the child will be done up to the age of 6 years. The study does not change the woman's doctor and does not interfere with the care of the treating physician.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Mothers and their child(ren) who were exposed to one of the following monotherapies in utero- Lamotrigine, Carbamazepine, Phenytoin, or Valproate. Fathers of the children and a first degree materal relative of the mother are also invited to have IQ testing and medical history
Contacts and Locations
Show 21 Study Locations| Principal Investigator: | Kimford J. Meador, M.D. | Emory University, Atlanta |
More Information
| Responsible Party: | Kimford J. Meador, M.D., Emory University |
| ClinicalTrials.gov Identifier: | NCT00021866 History of Changes |
| Other Study ID Numbers: | R01NS038455, 2RO1NS38455 |
| Study First Received: | August 8, 2001 |
| Last Updated: | June 23, 2011 |
| Health Authority: | United States: Federal Government |
|
epilepsy seizure pregnancy antiepileptic AED carbamazepine |
phenytoin valproate lamotrigine child behavior |
|
Cognition Disorders Epilepsy Seizures Delirium, Dementia, Amnestic, Cognitive Disorders Mental Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Signs and Symptoms Lamotrigine Anticonvulsants Phenytoin Valproic Acid Carbamazepine |
Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action GABA Agents Neurotransmitter Agents Physiological Effects of Drugs Antimanic Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Sensory System Agents |